Ikris Pharma
About Us Named Patient Program
Cities We Serve Contact Us

Crohn's & Ulcerative Colitis

Crohn's Disease and Ulcerative Colitis Medicines in India: Imported Biologic and Tablet Options

Written by Nitin Goswami Medically reviewed by Dr. Chirag C Shah Last updated
QUICK ANSWERCrohn's disease and ulcerative colitis are the two main forms of inflammatory bowel disease (IBD), a lifelong inflammation of the gut that comes and goes in flares. IBD is seen less often in India than in Europe or North America, but it is rising faster here than in the world as a whole [3]. A house-to-house survey in Punjab found ulcerative colitis in 44.3 of every 1,00,000 people [1]. When mesalamine, steroids or azathioprine do not keep the disease quiet, gastroenterologists may turn to newer biologic injections or a JAK tablet. 4 of these US FDA-approved medicines can be imported through Named Patient Program (NPP), each for a single patient with a specialist's prescription.
44.3
people with ulcerative colitis per 1,00,000 in a house-to-house survey of 51,910 people in Punjab, the first population study of its kind in India
Source: Sood et al., Gut 2003 [1]
43%
of Crohn's patients at three Indian IBD clinics had already been given anti-TB treatment before their diagnosis (71 of 166)
Source: Das et al., multicentre study [2]
2.34 vs 4.97
new IBD cases per 1,00,000 people a year in India against the world (age-standardised, 2019); India's rate is lower but climbing faster
Source: Global Burden of Disease analysis [3]
2.75x
rise in children diagnosed with IBD at a Gurugram hospital in 2010–2020 compared with the decade before (126 children in all)
Source: Medanta paediatric IBD study [4]

How Crohn's disease differs from ulcerative colitis

Both diseases come from an immune system that keeps attacking the lining of the gut. They are grouped together because they share symptoms and many medicines, yet they behave differently, and the difference shapes treatment.

FeatureCrohn's diseaseUlcerative colitis
Part of the gutAnywhere from mouth to anus, most often the end of the small intestine and the colon, with healthy patches in betweenOnly the large intestine (colon and rectum), starting at the rectum and spreading upwards without gaps
Depth of damageCan run through the full thickness of the bowel wallStays in the inner lining
Common complaintsBelly pain, diarrhoea, weight loss, sometimes fistulas or abscesses near the anusLoose motions with blood or mucus, urgency, cramps
Typical complicationsNarrowing (strictures) that block the bowel, fistulas, need for surgerySevere flares with heavy bleeding; long-standing disease raises the risk of colon cancer

In an Indian series of 182 Crohn's patients, the commonest complaints were loose motions in 68%, belly pain in 62% and losing weight in 57%, and 36% had needed an operation [2].

What Indian studies tell us about IBD

  • It is not rare here. The Punjab survey found 44.3 cases of ulcerative colitis per 1,00,000 people and 6.02 new cases per 1,00,000 per year; the authors noted this is not far below Europe and North America [1].
  • It is growing. Global Burden of Disease figures put India's 2019 IBD prevalence at 20.34 per 1,00,000 against 59.25 worldwide, but the yearly change in new cases was +0.05 in India while it was −0.18 globally [3]. AIIMS researchers expect India to carry one of the largest IBD burdens on earth [5].
  • Children are affected too. At one Gurugram centre, ulcerative colitis made up 60% and Crohn's 35% of 126 children with IBD, and 12.7% had very early onset IBD [4].
  • Family history is uncommon. Unlike in Western patients, very few Indian IBD patients have a relative with the disease [5], so a negative family history does not rule it out.

Crohn's or intestinal TB: why diagnosis can take years

Intestinal tuberculosis can look almost the same as Crohn's disease on a scope and on a scan. Because TB is common in India, many patients first receive a full course of anti-TB drugs. In the multicentre study above, 43% of Crohn's patients had taken anti-TB treatment before the right diagnosis was made [2]. Among children with Crohn's at the Gurugram centre, the median time to diagnosis was 52.5 months [4].

There is some good news. That same paediatric study saw empirical anti-TB use in Crohn's fall from 90% in the first decade to 5.8% in the second, and the time to diagnosis drop from 90 months to 21 months [4]. A Mumbai hospital that reviewed 15 years of records saw 348 people with Crohn's and 224 with intestinal TB, and the two did not rise and fall together [6]. TB still matters after diagnosis: every medicine on this page lowers some immune defences, so a TB check comes before the first dose.

Where imported biologics and JAK tablets fit in

Most Indian patients start on medicines that are easy to find here. In the Indian Crohn's series, 70% had received aminosalicylates, 42% steroids and 29% azathioprine [2]. The medicines on this page are for disease that is moderately to severely active, the wording used in every one of their US approvals. They act on different parts of the immune response:

  • Anti-TNF: Humira blocks tumour necrosis factor, one of the main signals that drives gut inflammation.
  • Gut-selective integrin blocker: Entyvio stops white blood cells from moving out of the blood into the lining of the gut.
  • IL-23 blocker: Skyrizi switches off interleukin-23, a messenger that keeps inflammation going.
  • JAK inhibitor tablet: Rinvoq is taken by mouth and dampens several signals inside immune cells at once. Its US approval in IBD is for people who have already tried at least one TNF blocker, or another approved systemic treatment when TNF blockers are not advisable.

Your gastroenterologist chooses between them after looking at the extent of disease, earlier treatment, infection risk and other health problems.

Imported Crohn's disease and ulcerative colitis medicines by type

All 4 medicines below are prescription-only. Tap a type to filter. Each card opens the full medicine page with dosage, storage and safety details.

Compare all 4 Crohn's disease and ulcerative colitis medicines

MedicineGeneric nameCrohn's disease and ulcerative colitis typeFormApproved by
HumiraadalimumabAnti-TNFPrefilled pen or syringe (injection under the skin)US FDA
EntyviovedolizumabGut-selective integrinIV infusion to start, then prefilled penUS FDA
Skyrizirisankizumab-rzaaIL-23 blockerIV infusion or injection to start, then injection under the skinUS FDA
RinvoqupadacitinibJAK inhibitor tabletTabletUS FDA

Checks your gastroenterologist will ask for

CheckWhy the label asks for itMedicines
Colonoscopy with biopsy, plus scan if neededConfirms Crohn's or ulcerative colitis, shows how much of the gut is involved and helps rule out intestinal TBAll four
Latent TB test (and chest X-ray)Humira and Rinvoq labels say to test for latent TB before starting and during treatment; Entyvio and Skyrizi labels say to consider TB testing firstHumira, Rinvoq, Entyvio, Skyrizi
Liver enzymes and bilirubinNeeded before Skyrizi is started for Crohn's or ulcerative colitis, and checked again during the first 12 weeks or moreSkyrizi
Vaccination recordThe Entyvio and Skyrizi labels ask for vaccines to be brought up to date before treatmentEntyvio, Skyrizi
Past TNF blocker treatmentRinvoq's IBD approval applies after a TNF blocker has not worked or was not toleratedRinvoq
Heart, clot and cancer historyRinvoq carries a boxed warning covering serious infections, deaths, cancers, heart attacks or strokes, and clots; Humira's boxed warning covers serious infections and cancerRinvoq, Humira

Permits, cold-chain storage and ongoing cost

None of these four is brought in from abroad without paperwork. The Form 12A application goes to CDSCO under the patient's name, with our pharmacist filling it in from the prescription and reports; the Form 12B permit then comes from CDSCO. The contents of both forms are explained on our Form 12A/12B import permit page.

Entyvio, Humira and Skyrizi are biologics, and their labels require refrigeration at 2–8 °C. Entyvio, and Skyrizi for ulcerative colitis, begin with drip infusions given in a hospital or day-care unit; Skyrizi for Crohn's can start either as infusions or as injections. For these, we can ship directly to the hospital's pharmacy in an insulated pack with a temperature recorder, as described under hospital delivery across India. Rinvoq tablets are stored at normal room temperature (2–25 °C, per its label).

IBD medicines are usually continued for years once they work, so plan for cost early. Manufacturer schemes, government programmes and charities that may help are collected on one page: help with treatment costs.

How to get these Crohn's disease and ulcerative colitis medicines in India

1

Prescription
Your doctor prescribes the medicine.

2

Share documents
Send the prescription and latest reports through Online Order.

3

Import paperwork
Our team checks the source and the import permissions.

4

Delivery
Delivered with the right storage, including cold chain.

Read How to Order and Indian import regulations. We also serve patients in Delhi NCR, Bangalore, Chennai, Mumbai, Kolkata, Hyderabad and Pune.

Has your doctor prescribed one of these medicines?

Share the prescription and we will guide you on availability and next steps.

Online Order

Read more about Crohn's disease and ulcerative colitis

References

  1. Sood A, Midha V, Sood N, Bhatia AS, Avasthi G. Incidence and prevalence of ulcerative colitis in Punjab, North India. Gut. 2003;52(11):1587-90. https://pubmed.ncbi.nlm.nih.gov/14570727/
  2. Das K, Ghoshal UC, Dhali GK, Benjamin J, Ahuja V, Makharia GK. Crohn's disease in India: a multicenter study from a country where tuberculosis is endemic. Dig Dis Sci. 2009;54(5):1099-107. https://pubmed.ncbi.nlm.nih.gov/18770037/
  3. Giri S, Jena A, Kumar-M P, et al. Burden of inflammatory bowel disease in India: analysis of the Global Burden of Disease study from 1990 to 2019. Intest Res. 2026;24(1):84-94. https://pubmed.ncbi.nlm.nih.gov/39910905/
  4. Mohan N, Deswal S, Bhardwaj A. Spectrum and trend of pediatric inflammatory bowel disease: a two-decade experience from northern India. Indian J Gastroenterol. 2024;43(1):208-214. https://pubmed.ncbi.nlm.nih.gov/37943479/
  5. Kedia S, Ahuja V. Epidemiology of inflammatory bowel disease in India: the great shift east. Inflamm Intest Dis. 2017;2(2):102-115. https://pubmed.ncbi.nlm.nih.gov/30018961/
  6. Dhoble P, Desai D, Abraham P. Is the rise in Crohn's disease in India accompanied by a fall in intestinal tuberculosis? A single-center experience. Indian J Tuberc. 2021;68(2):210-214. https://pubmed.ncbi.nlm.nih.gov/33845954/
  7. US FDA prescribing information for Entyvio, Humira, Rinvoq and Skyrizi (DailyMed). https://dailymed.nlm.nih.gov/dailymed/

This page gives general information only and does not replace medical advice. All medicines listed are prescription-only and must be used under a qualified doctor.

Crohn's & Ulcerative Colitis Medicines:
Questions Patients Ask

Short answers to what patients and families ask us most.

More FAQs

Meet the NPP Assistant: ask us anything about NPP